Payers Open to Innovative Financing Mechanisms for High Cost Gene Therapies

Eric NormanFoCUS, Research Briefs

In a broad survey, payers favor performance based milestone contracts and risk pools strategies to absorb the surge of high cost gene therapy products expected to enter the market over … Read More

Mark Trusheim featured on Bloomberg News

Eric NormanNews

BLOOMBERG: Novartis’s $475,000 Cancer Breakthrough Heralds New Era of Cures There are more than 600 gene and cell therapies in clinical trials today, according to Mark Trusheim, a strategic director … Read More

Next Wave Forum

Eric NormanLEAPS, News

December 12–13, 2017 at MIT Biomedical science is outpacing the system.
Barriers prevent patients’ access to innovations. Are you ready to innovation how we innovate? The Next Wave in Adaptive Biomedical … Read More